These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 38952401)

  • 1. Comparison of Tumor Non-specific and PD-L1 Specific Imaging by Near-Infrared Fluorescence/Cerenkov Luminescence Dual-Modality In-situ Imaging.
    Zhang L; Zhao L; Lin X; Zhao S; Pan W; Wang D; Sun Z; Li J; Liang Z; Zhang R; Jiang H
    Mol Imaging; 2024; 23():15353508241261473. PubMed ID: 38952401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radioimmunotherapy study of
    Zhang L; Zhao S; Jiang H; Zhang R; Zhang M; Pan W; Sun Z; Wang D; Li J
    EJNMMI Res; 2022 Oct; 12(1):70. PubMed ID: 36307610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Near-infrared fluorescence-labeled anti-PD-L1-mAb for tumor imaging in human colorectal cancer xenografted mice.
    Zhang M; Jiang H; Zhang R; Jiang H; Xu H; Pan W; Gao X; Sun Z
    J Cell Biochem; 2019 Jun; 120(6):10239-10247. PubMed ID: 30609118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Pretargeted Imaging Strategy for Immune Checkpoint Ligand PD-L1 Expression in Tumor Based on Bioorthogonal Diels-Alder Click Chemistry.
    Qiu L; Tan H; Lin Q; Si Z; Mao W; Wang T; Fu Z; Cheng D; Shi H
    Mol Imaging Biol; 2020 Aug; 22(4):842-853. PubMed ID: 31741201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ImmunoPET/NIRF/Cerenkov multimodality imaging of ICAM-1 in pancreatic ductal adenocarcinoma.
    Li M; Wei W; Barnhart TE; Jiang D; Cao T; Fan K; Engle JW; Liu J; Chen W; Cai W
    Eur J Nucl Med Mol Imaging; 2021 Aug; 48(9):2737-2748. PubMed ID: 33537836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD146-targeted immunoPET and NIRF Imaging of Hepatocellular Carcinoma with a Dual-Labeled Monoclonal Antibody.
    Hernandez R; Sun H; England CG; Valdovinos HF; Ehlerding EB; Barnhart TE; Yang Y; Cai W
    Theranostics; 2016; 6(11):1918-33. PubMed ID: 27570560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual-Modality Image-Guided Surgery of Prostate Cancer with a Radiolabeled Fluorescent Anti-PSMA Monoclonal Antibody.
    Lütje S; Rijpkema M; Franssen GM; Fracasso G; Helfrich W; Eek A; Oyen WJ; Colombatti M; Boerman OC
    J Nucl Med; 2014 Jun; 55(6):995-1001. PubMed ID: 24700882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liposomal nanohybrid cerasomes targeted to PD-L1 enable dual-modality imaging and improve antitumor treatments.
    Du Y; Liang X; Li Y; Sun T; Xue H; Jin Z; Tian J
    Cancer Lett; 2018 Feb; 414():230-238. PubMed ID: 29175457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimizing Immuno-PET Imaging of Tumor PD-L1 Expression: Pharmacokinetic, Biodistribution, and Dosimetric Comparisons of
    Bouleau A; Nozach H; Dubois S; Kereselidze D; Chevaleyre C; Wang CI; Evans MJ; Lebon V; Maillère B; Truillet C
    J Nucl Med; 2022 Aug; 63(8):1259-1265. PubMed ID: 34933891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-L1 Detection in Tumors Using [(64)Cu]Atezolizumab with PET.
    Lesniak WG; Chatterjee S; Gabrielson M; Lisok A; Wharram B; Pomper MG; Nimmagadda S
    Bioconjug Chem; 2016 Sep; 27(9):2103-10. PubMed ID: 27458027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cerenkov luminescence imaging is an effective preclinical tool for assessing colorectal cancer PD-L1 levels in vivo.
    Zhao S; Pan W; Jiang H; Zhang R; Jiang H; Liang Z; Hu H
    EJNMMI Res; 2020 Jun; 10(1):64. PubMed ID: 32542442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intratherapeutic biokinetic measurements, dosimetry parameter estimates, and monitoring of treatment efficacy using cerenkov luminescence imaging in preclinical radionuclide therapy.
    Timmermand OV; Tran TA; Strand SE; Axelsson J
    J Nucl Med; 2015 Mar; 56(3):444-9. PubMed ID: 25655628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PET Imaging of Tumor PD-L1 Expression with a Highly Specific Nonblocking Single-Domain Antibody.
    Lv G; Sun X; Qiu L; Sun Y; Li K; Liu Q; Zhao Q; Qin S; Lin J
    J Nucl Med; 2020 Jan; 61(1):117-122. PubMed ID: 31253743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multifunctional Probe Based on "Chemical Antibody-Aptamer" for Noninvasive Detection of PD-L1 Expression in Cancer.
    Kong S; Liu Q; Chen Y; Liang B; Zhou Y; Lin J; Xie M; Qiu L
    Mol Pharm; 2024 Jan; 21(1):255-266. PubMed ID: 38093483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual-Modality Immuno-PET and Near-Infrared Fluorescence Imaging of Pancreatic Cancer Using an Anti-Prostate Stem Cell Antigen Cys-Diabody.
    Zettlitz KA; Tsai WK; Knowles SM; Kobayashi N; Donahue TR; Reiter RE; Wu AM
    J Nucl Med; 2018 Sep; 59(9):1398-1405. PubMed ID: 29602820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors.
    Chatterjee S; Lesniak WG; Gabrielson M; Lisok A; Wharram B; Sysa-Shah P; Azad BB; Pomper MG; Nimmagadda S
    Oncotarget; 2016 Mar; 7(9):10215-27. PubMed ID: 26848870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In Vivo Imaging of the Programmed Death Ligand 1 by
    González Trotter DE; Meng X; McQuade P; Rubins D; Klimas M; Zeng Z; Connolly BM; Miller PJ; O'Malley SS; Lin SA; Getty KL; Fayadat-Dilman L; Liang L; Wahlberg E; Widmark O; Ekblad C; Frejd FY; Hostetler ED; Evelhoch JL
    J Nucl Med; 2017 Nov; 58(11):1852-1857. PubMed ID: 28588151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Noninvasive Imaging and Quantification of Radiotherapy-Induced PD-L1 Upregulation with
    Ehlerding EB; Lee HJ; Barnhart TE; Jiang D; Kang L; McNeel DG; Engle JW; Cai W
    Bioconjug Chem; 2019 May; 30(5):1434-1441. PubMed ID: 30973703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-L1 detection using
    Vento J; Mulgaonkar A; Woolford L; Nham K; Christie A; Bagrodia A; de Leon AD; Hannan R; Bowman I; McKay RM; Kapur P; Hao G; Sun X; Brugarolas J
    J Immunother Cancer; 2019 Jun; 7(1):144. PubMed ID: 31155004
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Cheng Y; Shi D; Xu Z; Gao Z; Si Z; Zhao Y; Ye R; Fu Z; Fu W; Yang T; Xiu Y; Lin Q; Cheng D
    Mol Pharm; 2022 Oct; 19(10):3551-3562. PubMed ID: 35244407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.